[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Malaya\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":691},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,48,78,107,131,158,188,213,233,259,290,321,354,383,409,438,469,499,520,543,569,591,612,637,666],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100643848","the-effect-of-full-versus-partial-coverage-thermoformed-retainers-in-dual-retention-with-a-lower-bonded-retainer-on-periodontal-orthodontic-and-patient-reported-outcomes-100643848",false,"NCT07669129","The Effect of Full Versus Partial Coverage Thermoformed Retainers in Dual Retention With a Lower Bonded Retainer, on Periodontal, Orthodontic, and Patient-Reported Outcomes","The Effect of Full Versus Partial Coverage Thermoformed Retainers in Dual Retention With a Lower Bonded Retainer, on Periodontal, Orthodontic, and Patient-Reported Outcomes: A Randomised Controlled Trial","Inclusion Criteria:\n\n* Aged over 18 years.\n* Controlled systemic diseases and conditions.\n* Probing pocket depth ≤ 3 mm\n* Bleeding on probing \\\u003C 10 per cent\n* Full mouth plaque scores of less than 20 per cent\n* Just completed active orthodontic treatment involving lower arch\n* Patient consent to dual retention in the lower arch\n\nExclusion Criteria:\n\n* Require a Hawley retainer in the lower arch.\n* Patients in retention phase requiring replacement of retainers\n* Uncontrolled systemic disease, including chronic or metabolic diseases.\n* Pregnant or lactating mothers within six months postpartum.\n* Taking medications that affect gingival health and architecture.\n* Have one or more missing anterior teeth.\n* Have congenital craniofacial deformities and syndromes, including cleft lip and\u002F or palate\n* Cigarette or vape smokers",true,"ALL","18 Years",{"count":21,"type":22},42,"ESTIMATED","INTERVENTIONAL",[25],"NA","After braces are removed, teeth may move back toward their original positions. Retainers are used to help keep teeth straight after orthodontic treatment. This study compares two types of clear removable retainers used together with a fixed wire retainer behind the lower front teeth. One retainer covers the entire inner surface of the teeth (full coverage), while the other covers only part of the inner surface (partial coverage).\n\nThe purpose of this study is to find out whether the two retainer designs differ in their effects on gum health, comfort, retainer breakages, stability of the orthodontic correction, comfort, and compliance. The findings from this study may help orthodontists choose the most suitable retainer design for future patients.\n\nParticipants in this study will receive a fixed wire retainer on the lower front teeth and upper and lower clear removable retainers. They will be randomly assigned to receive either the full coverage or partial coverage lower retainer. Participants will attend follow-up visits at 1 month, 3 months, and 6 months after starting retainer wear. At these visits, the orthodontist will examine the teeth, gums, and retainers, and participants will complete a short questionnaire about their experience wearing the retainer.\n\nThis study excluded participants who are pregnant or breastfeeding within the first 6 months, have uncontrolled medical conditions or gum disease, smoke or vape, require a Hawley retainer instead of a clear retainer, or have missing front teeth or certain jaw conditions.\n\nParticipants may benefit from receiving retainers, oral hygiene care, and regular monitoring of their teeth and gum health at no additional cost. Participants will also receive an oral care kit during the debond appointment and at the 3-month and 6-month review visits.\n\nPossible risks include breakage of the retainers, which may require repair or replacement, gum problems if oral hygiene is not maintained, and slight tooth movement despite retainer use. If gum problems develop, appropriate cleaning and referral for further treatment may be provided. Replacement retainers required during the study period will be provided free of charge.",[28],"Orthodontic Retention",[30,31,32,33,34],"Orthodontic retention","clear retainer","fixed bonded retainer","periodontal health","breakage","NOT_YET_RECRUITING","2026-06-21",{"date":38,"type":39},"2026-06-25","ACTUAL",{"date":41,"type":22},"2026-06-01",{"date":43,"type":22},"2027-09-30",{"name":45,"class":46},"University of Malaya","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":47},"100641568","phase-3-effectiveness-of-single-and-dual-silver-fluoride-application-100641568","NCT07658690","Effectiveness of Single and Dual Silver Fluoride Application","The Effectiveness of Single and Dual Silver Fluoride (SF) Applications on Dentine Caries Among Malaysian Preschool Children: A Randomised Controlled Trial","Inclusion Criteria:\n\n1. Children aged 4-6 years enrolled in selected preschools.\n2. Presence of at least one active dentinal caries lesion.\n3. Parental or guardian consent obtained.\n4. Asymptomatic cavitated dentine carious lesions in primary teeth.\n5. Parents\u002Fcaregivers who understand the Malay language.\n\nExclusion Criteria:\n\n1. Clinical signs or symptoms of irreversible pulpitis or dental abscess\u002Ffistula.\n2. Systemic illness or medical contraindications for SF use.\n3. Developmental abnormalities of tooth structure, including amelogenesis imperfecta or dentinogenesis imperfecta.\n4. History of allergy or sensitivity to dental materials, including silver or fluoride contained in silver fluoride (SF).\n5. Children who have received professionally applied fluoride within the past six months at the time of recruitment.\n6. Arrested caries lesion.\n7. Children presenting with oral ulceration or mucositis.\n8. Uncooperative behaviour precluding oral examination.\n9. Children with pre-shedding tooth mobility","4 Years","6 Years",{"count":58,"type":22},138,[60],"PHASE3","This is a community-based, parallel-group, double-blinded randomised controlled trial aimed at evaluating the effectiveness of single and dual applications of 38% Silver Fluoride (SF) in arresting dentinal caries among Malaysian preschool children aged 4 to 6 years.\n\nThe main questions this study aims to answer are:\n\ni) Does dual application of 38% Silver Fluoride differ from single application in arresting dentinal caries lesions after 6 months? ii) How does SF application influence oral health-related quality of life (OHRQoL) among preschool children, as measured by the Malay-ECOHIS questionnaire? iii) Is there a correlation between caries arrest and changes in Oral Health-Related Quality of Life (OHRQoL) measured using the Malay-ECOHIS questionnaire?\n\nResearchers will compare children receiving a single application of 38% Silver Fluoride with those receiving dual applications to determine whether more frequent application improves caries arrest outcomes.\n\nParticipants will:\n\ni) Undergo oral examination for assessment of dentinal caries using ICDAS criteria.\n\nii) Receive 38% Silver Fluoride application at baseline, with the dual-application group receiving an additional application at 3 months.\n\niii) Attend follow-up assessments at 3 and 6 months to evaluate caries arrest status.\n\niv) Have parents or guardians complete the Malay-ECOHIS questionnaire to assess changes in OHRQoL.",[63],"Dentine Caries",[65,66,67,68,69],"Silver Fluoride","Caries Arrest","Randomised Controlled Trial","Preschool Children","Silver Diamine Fluoride","2026-06-16",{"date":72,"type":39},"2026-06-22",{"date":74,"type":22},"2026-09",{"date":76,"type":22},"2028-02",{"name":45,"class":46},{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":47},"100643128","breast-milk-versus-barrier-creams-for-diaper-dermatitis-in-children-aged-0-24-months-100643128","NCT07633808","Breast Milk Versus Barrier Creams for Diaper Dermatitis in Children Aged 0-24 Months","Nurse-Led Management of Diaper Dermatitis in Children Aged 0-24 Months: A Mixed-Methods Study of Breast Milk Versus Barrier Creams","NURSE-DD","Inclusion Criteria:\n\nChildren aged 0 to 24 months. Diagnosis of mild-to-moderate diaper dermatitis based on clinical assessment. Caregiver willing and able to comply with study procedures and follow-up requirements.\n\nAvailability of maternal breast milk for participants allocated to the maternal breast milk group.\n\nWritten informed consent provided by the child's parent or legal guardian.\n\nExclusion Criteria:\n\n* Severe diaper dermatitis requiring immediate medical treatment. Suspected or confirmed fungal, bacterial, or other secondary skin infection requiring alternative treatment.\n\nCurrent use of systemic antibiotics or topical medications that may interfere with outcome assessment.\n\nKnown hypersensitivity or contraindication to barrier cream products used in the study.\n\nPresence of significant dermatological or medical conditions that may affect skin healing or study outcomes.\n\nParticipation in another clinical study during the study period.","24 Months",{"count":88,"type":22},160,[25],"Diaper dermatitis is a common inflammatory skin condition among children aged 0-24 months. Although commercial barrier creams are widely used, maternal breast milk has been suggested as a safe, accessible, and low-cost alternative due to its antimicrobial and anti-inflammatory properties. However, evidence regarding its effectiveness within structured nurse-led management programs in primary healthcare settings remains limited.\n\nThis study aims to compare the effectiveness of topical maternal breast milk and commercial barrier creams in the management of mild-to-moderate diaper dermatitis among children aged 0-24 months attending primary healthcare clinics in Palestine. The study will use a mixed-methods design consisting of a pragmatic randomized controlled trial followed by qualitative interviews with nurses. Clinical outcomes will be assessed using the Diaper Dermatitis Severity Scale (DDSS), and qualitative findings will explore the feasibility and implementation of the nurse-led intervention in routine practice.",[92],"Diaper Dermatitis",[92,94,95,96,97,98],"Diaper Rash","Breast Milk","Maternal Breast Milk","Barrier Creams","Nurse-Led Intervention","2026-06-09",{"date":101,"type":39},"2026-06-11",{"date":103,"type":22},"2026-06",{"date":105,"type":22},"2026-12",{"name":45,"class":46},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":18,"minAge":114,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":47},"100642796","evaluating-the-effectiveness-of-mobithron-xtra-in-patients-with-primary-knee-osteoarthritis-over-a-3-month-period-100642796","NCT07643662","Evaluating the Effectiveness of Mobithron Xtra in Patients With Primary Knee Osteoarthritis Over a 3-month Period","Observational Study to Evaluate the Effectiveness of Mobithron Xtra in Patients With Primary Knee Osteoarthritis Over a 3-month Period","Inclusion Criteria:\n\n* Adults ≥40 years with primary knee osteoarthritis (OA)\n* Radiographic diagnosis of primary knee OA (Grade 2 or 3 on Kellgren-Lawrence scale)\n* Stable physiotherapy regimen for ≥3 months (if applicable).\n* Baseline VAS score ≥ 5\n* No prior surgical intervention for the affected knee\n\nExclusion Criteria:\n\n* Secondary OA (such as post-traumatic and inflammatory arthritis)\n* Grade IV Primary OA\n* Patients on analgesia (e.g., paracetamol, NSAIDs)\n* Patients on Mobithron (P\u002FAdvance\u002FXtra) or glucosamine products\n* Recent intra-articular injections within 6 months\n* Recent\u002Fplanned knee surgery within 3 months\n* Severe comorbidities or cognitive impairment","40 Years",{"count":116,"type":22},100,"OBSERVATIONAL","Knee osteoarthritis is a common condition that causes knee pain, stiffness, reduced mobility, and difficulty performing daily activities. Many patients seek non-surgical treatment options to help manage their symptoms and improve their quality of life.\n\nThis study aims to evaluate the effectiveness and safety of Mobithron® Xtra, an oral health supplement containing hyaluronic acid, undenatured type II collagen, and Boswellia serrata extract, in adults with primary knee osteoarthritis. Participants will take Mobithron® Xtra once daily for 3 months as part of their routine care.\n\nThe study will observe changes in knee pain, stiffness, physical function, treatment satisfaction, and overall perception of improvement using validated patient-reported outcome measures, including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Visual Analogue Scale (VAS), Treatment Satisfaction Questionnaire for Medication (TSQM), and Patient Global Impression of Change (PGIC).\n\nThis is a prospective, multicentre observational study involving patients receiving treatment in participating general practitioner clinics throughout Malaysia. No experimental procedures will be performed, and participants will continue to receive standard clinical care. Safety will be monitored throughout the study by documenting any adverse events reported by participants.\n\nThe findings from this study may provide valuable real-world evidence regarding the role of Mobithron® Xtra in improving symptoms and quality of life among patients with primary knee osteoarthritis.",[120],"Osteoarthritis (OA) of the Knee",[122,123],"knee osteoarthritis","mobitron","2026-06-08",{"date":101,"type":39},{"date":127,"type":22},"2026-07",{"date":129,"type":22},"2027-12",{"name":45,"class":46},{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":18,"minAge":138,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":157},"100621359","impact-of-chemotherapy-dose-reductions-on-survival-outcomes-among-older-nsclc-patients-without-actionable-mutations-100621359","NCT07369596","Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations","Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations: A Retrospective Cohort Study.","Inclusion Criteria:\n\n* Age ≥65 years\n* Histologically confirmed stage IV NSCLC\n* Negative for EGFR mutation, ALK rearrangement, and ROS1 fusion\n* Treated with at least ONE cycle of first-line chemotherapy\n\nExclusion Criteria:\n\n* Patients who received targeted therapy or immunotherapy as monotherapy in the first-line setting\n* Incomplete survival data","65 Years",{"count":140,"type":22},150,"Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity.\n\nThis study seeks to evaluate chemotherapy dosing patterns and associated survival outcomes in older patients.",[143],"Non Small Cell Lung Carcinoma NSCLC",[145,146,147],"NSCLC","older patients","chemotherapy","RECRUITING","2026-05-30",{"date":151,"type":39},"2026-06-02",{"date":153,"type":39},"2026-01-01",{"date":155,"type":22},"2026-12-31",{"name":45,"class":46},4,{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":169,"conditions":170,"keywords":175,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":186,"leadSponsor":187,"locationsCount":4},"100574724","intensive-music-therapy-on-cognitive-function-in-subacute-stroke-rehabilitation-in-malaysia-100574724","NCT06763003","Intensive Music Therapy on Cognitive Function in Subacute Stroke Rehabilitation in Malaysia","Feasibility Randomised Controlled Trial of Intensive Music Therapy on Cognitive Function in Subacute Stroke Rehabilitation in Malaysia","Inclusion Criteria:\n\n* Diagnosed with ischemic or haemorrhagic stroke confirmed by CT scan\n* Duration of stroke within the first 3 months\n* Aged 18 - 75 years old\n* Ability to provide informed consent\n* Understands Bahasa Melayu or English with basic communication abilities to follow instructions during therapy sessions\n* Mild to moderate cognitive impairments with MoCA score of 10-25.\n\nExclusion Criteria:\n\n* Severe aphasia\n* Significant uncorrected hearing or visual impairments preventing engagement in music therapy.\n* Severe or unstable medical conditions (e.g., uncontrolled hypertension or diabetes).\n* Medications that significantly impair cognition or motor function (e.g., high dose sedatives).\n* History of neurological diseases other than stroke (eg, Parkinson's disease).","75 Years",{"count":167,"type":22},36,[25],"The purpose of this study is to explore whether intensive music therapy can help improve cognitive functions like memory, attention, and decision-making skills in stroke patients who are undergoing rehabilitation.\n\nThis is a feasibility study, meaning it's also designed to see how practical it is to include music therapy as part of stroke rehabilitation. The investigators want to learn how well patients can participate in and stick with this type of therapy, and whether it fits well with other treatments that stroke patients usually receive. By understanding this, the investigators can assess the resources, staff training, and planning needed for music therapy to be part of stroke recovery in the future.\n\nThe study will also help the investigators estimate the effects of music therapy, which will be used to design a larger, more detailed study in the future.",[171,172,173,174],"Rehabilitation","Cognition","Stroke","Attention",[176,177,178,179,180,181],"Music therapy","randomised controlled trial","rehabilitation","stroke","cognition","attention","2026-04-27",{"date":184,"type":39},"2026-05-01",{"date":184,"type":22},{"date":155,"type":22},{"name":45,"class":46},{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":165,"enrollmentInfo":195,"targetDuration":4,"studyType":23,"phases":197,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":212,"locationsCount":47},"100602940","hybrid-exercise-program-for-heart-disease-effect-on-health-and-quality-of-life-100602940","NCT07130045","Hybrid Exercise Program for Heart Disease: Effect on Health and Quality of Life","Effect of Hybrid Endurance and Strength Training (HyBEST) on Health-Related Outcomes and Quality of Life in Patients With Coronary Artery Disease During Phase II Cardiac Rehabilitation Program","Inclusion Criteria:\n\n* Age of 18 years or older.\n* Diagnosed with coronary artery disease (CAD), with or without invasive treatment, maintaining a normal sinus rhythm and preserved left ventricular ejection fraction (LVEF).\n* In a stable clinical condition.\n* capable of regularly attending a supervised exercise program.\n* Able to complete questionnaires in English or Malay.\n\nExclusion Criteria:\n\n* They exhibited abnormal responses during the initial exercise test, such as irregular haemodynamic responses, ST segment depression greater than 2 mm, or any ventricular fibrillation.\n* Their forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC) is less than 50% of the predicted value.\n* They cannot participate in exercise testing due to non-cardiac limitations.\n* They have been hospitalized due to heart failure within the past year.\n* They have uncontrollable hypertension.",{"count":196,"type":22},84,[25],"Cardiac rehabilitation (CR) participation remains suboptimal, partly due to logistical challenges and limited access to center-based programs. Hybrid Endurance-Strength Training (HybEST) offers an alternative model by combining supervised endurance and strength exercises with home-based components. The main questions it aims to answer are:\n\n* Does a hybrid exercise program significantly improve a patient's body function and structures \\[exercise capacity, body composition, and muscle strength\\] compared to usual care?\n* Does a hybrid exercise program significantly improve a patient's activity \\[functional capacity, physical activity, and total energy expenditure\\] compared to usual care?\n* Does a hybrid exercise program significantly improve a patient's participation \\[health-related quality of life\\] compared to usual care?\n\nThis single-center, two-arm parallel randomized clinical trial aims to evaluate the effects of HybEST on health-related outcomes and quality of life among patients with coronary artery disease in Phase II CR. Eligible participants will be randomly assigned in a 1:1 ratio to either the HybEST intervention group or the standard CR control group using a lottery method, specifically the sealed envelope approach. Assessments will be conducted at baseline (T0), Week 5 (T2), and Week 9 (T3) to measure changes in health-related outcomes and quality of life.",[200],"Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))",[202,203,204,205],"coronary artery disease","combined training","hybrid","cardiac rehabilitation","2026-04-13",{"date":208,"type":39},"2026-04-17",{"date":210,"type":22},"2026-10",{"date":129,"type":22},{"name":45,"class":46},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":47},"100633837","probiotics-as-adjunctive-therapy-in-the-management-of-periodontitis-100633837","NCT07531875","Probiotics as Adjunctive Therapy in the Management of Periodontitis","1. The subject has given their written consent to participate in the trial.\n2. All subjects must be aged \\>18 years old, not pregnant, and presented with number of teeth \\> 12\n3. Diagnosis for periodontitis Stage III and IV, will be according to 2017 the American Academy of Periodontology (AAP) and European Federation of Periodontology (EFP) classification\n4. Has had 1 round of periodontal therapy within 3-6 months' time from recruitment date, and currently presented with at least 4 residual pockets with pocket depth 5mm and above.",{"count":220,"type":22},20,[25],"The goal of this clinical trials is to learn about the effect of taking Prodentis on a long term basis following periodontal therapy. The main question it aims to answer is\n\n1\\. what is the effect of long-term consumption of Prodentis on regulating periodontal health and systemic immune-response, when compare to only taking it for 3 months post RSD?",[224],"Periodontitis","2026-04-09",{"date":227,"type":39},"2026-04-15",{"date":229,"type":39},"2025-11-10",{"date":231,"type":22},"2028-12",{"name":45,"class":46},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":18,"minAge":241,"maxAge":165,"enrollmentInfo":242,"targetDuration":4,"studyType":23,"phases":243,"briefSummary":244,"conditions":245,"keywords":248,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":47},"100633113","enhancing-attention-and-processing-speed-through-home-based-music-rehabilitation-program-after-stroke-in-malaysia-100633113","NCT07522463","Enhancing Attention and Processing Speed Through Home-based Music Rehabilitation Program After Stroke in Malaysia","Enhancing Attention and Processing Speed Through Home-based Music Rehabilitation Program After Stroke in Malaysia: A Feasibility Random Controlled Study","HMRPAS","Inclusion Criteria:\n\n* Diagnosed with ischemic or haemorrhagic stroke confirmed by CT scan\n* 18 to 70 years old\n* Duration of stroke within the first one year\n* Ability to provide informed consent\n* Understands Bahasa Melayu or English with basic communication abilities to follow instructions during therapy sessions\n* Mild to moderate cognitive impairments with MoCA score of 10-25, with incomplete score for the attention sections\n* Availability of caregiver (formal or informal) who can assist in the music therapy, monitor and give feedback during the music therapy sessions at home\n* Have one normal functioning hand to perform the movements during the music therapy rehabilitation program\n* Have good balance and able to sit upright\n\nExclusion Criteria:\n\n* Severe aphasia\n* Significant uncorrected hearing or visual impairments preventing engagement in music therapy.\n* Severe or unstable medical conditions (e.g., uncontrolled hypertension or diabetes).\n* Medications that significantly impair cognition or motor function (e.g., high-dose sedatives).\n* History of neurological diseases other than stroke (eg, Parkinson's disease).","55 Years",{"count":167,"type":22},[25],"Stroke often leads to significant cognitive impairment, impacting quality of life. While existing rehabilitation options exist, there's a need for innovative, accessible, and patient-centered solutions. Research suggests music can engage multiple brain networks associated with sensory and motor processes, cognition, and affective regulation, potentially enhancing cognitive functions like attention and processing speed as well. Home-based interventions have also demonstrated positive impacts on rehabilitation adherence and outcomes. Building on this foundation, this study proposes to develop and pilot test a home-based musical rehabilitation program to improve attention and processing speed in Malaysian stroke survivors.",[173,174,246,247],"Rehabilitation Program","Music Intervention",[174,249,250,173,251],"Processing Speed","Home-based Music Rehabilitation Program","Malaysia","2026-04-07",{"date":206,"type":39},{"date":255,"type":22},"2026-04-01",{"date":257,"type":22},"2026-10-31",{"name":45,"class":46},{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":18,"minAge":267,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":23,"phases":270,"briefSummary":271,"conditions":272,"keywords":274,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":47},"100627751","small-study-comparing-two-pain-medicines-in-teenagers-for-pain-control-after-scoliosis-corrective-surgery-100627751","NCT07452705","Small Study Comparing Two Pain Medicines in Teenagers for Pain Control After Scoliosis Corrective Surgery.","Patient-Controlled Analgesia (PCA) With Ketamine-Morphine (PCA KetaMorph) vs PCA Morphine for Postoperative Analgesia in Idiopathic Scoliosis Surgery - A Randomized Controlled Trial","KetaMorph","Inclusion criteria:\n\n1. Aged \\> 10 years old\n2. Idiopathic scoliosis scheduled for single-stage posterior spinal fusion (PSF).\n3. American Society of Anaesthesiologists (ASA) physical status I-II.\n\nExclusion criteria:\n\n1. Known hypersensitivity to morphine, ketamine or formulation excipients.\n2. Hepatic dysfunction (ALT or AST \\> 2 × upper limit of normal).\n3. Renal impairment (eGFR ≤ 60 mL min-¹ 1·73 m-²).\n4. Uncontrolled asthma or severe restrictive lung disease.\n5. Cardiac disease or clinically significant arrhythmia.\n6. Epilepsy.\n7. Intellectual disability precluding PCA use.\n8. Chronic opioid therapy or pre-operative pain \\> 3 months.\n9. Concomitant monoamine-oxidase inhibitor or tricyclic antidepressant therapy.\n10. History of severe postoperative delirium.","10 Years",{"count":269,"type":22},114,[25],"The goal of this clinical trial is to evaluate whether adding low-dose ketamine to PCA morphine reduces opioid requirements after posterior spinal fusion surgery in adolescent idiopathic scoliosis patients. Selected patients aged 10-18 years undergoing elective AIS surgery at University Malaya Medical Centre will be randomised to ketamine-morphine or morphine-only PCA. The primary outcome is cumulative morphine consumption at 48 hours, with secondary outcomes including pain scores, opioid-related adverse effects, time to ambulation, and patient satisfaction. This study aligns with national priorities for safe opioid stewardship and enhanced peri-operative care in Malaysia.",[273],"Adolescent Idiopathic Scoliosis (AIS)",[275,276,277,278,279,280,281],"Adolescent","Analgesia","Ketamine","Morphine","Pain management","Pain-controlled","Spinal fusion","2026-03-01",{"date":284,"type":39},"2026-03-05",{"date":286,"type":22},"2026-02-02",{"date":288,"type":22},"2028-01-30",{"name":45,"class":46},{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":298,"enrollmentInfo":299,"targetDuration":301,"studyType":117,"phases":4,"briefSummary":302,"conditions":303,"keywords":307,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":47},"100625284","multilevel-ecological-and-com-b-determinants-of-medication-adherence-in-adults-with-diabetes-100625284","NCT07420634","Multilevel Ecological and COM-B Determinants of Medication Adherence in Adults With Diabetes","Multilevel Ecological Determinants of Medication Adherence Among Diabetes Patients: A Health Ecology-COM-B Framework Analysis","ADHECOM","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosed with at least one chronic disease (e.g., diabetes mellitus, hypertension, cardiovascular disease, chronic respiratory disease, chronic kidney disease) for a minimum duration of six months\n* Prescribed long-term medication therapy\n* Able to understand and respond to the study questionnaire\n* Willing to provide written informed consent\n\nExclusion Criteria:\n\n* Patients with acute medical conditions requiring immediate care\n* Individuals with severe cognitive impairment or psychiatric illness that would preclude reliable participation\n* Patients who are terminally ill\n* Patients unwilling to participate or provide consent","70 Years",{"count":300,"type":22},220,"1 Day","This observational study aims to understand why some adults with diabetes find it difficult to take their medicines as prescribed. Medication adherence is essential for controlling blood sugar levels and preventing complications, yet many patients face challenges that go beyond personal motivation.\n\nThe study will examine multiple factors that may influence medication-taking behavior, including patients' understanding of their medicines, beliefs about treatment, family and social support, communication with healthcare providers, and practical issues such as medicine cost, availability, and distance to care. These factors will be analyzed using a structured behavioral framework to better understand how capability, opportunity, and motivation contribute to adherence.\n\nBy identifying the most important barriers and supports across different levels, this research aims to provide evidence that can guide patient-centered care strategies and improve medication adherence in diabetes management.",[304,305,306],"Diabetes Mellitus","Diabetes Mellitus Type 2","Medication Adherence",[308,309,306,304,310,311,312],"Health Ecology Model","COM-B Model","Capability Opportunity Motivation","Behavioral Determinants","Medication Literacy","2026-02-12",{"date":315,"type":39},"2026-02-19",{"date":317,"type":39},"2025-12-15",{"date":319,"type":22},"2026-08-30",{"name":45,"class":46},{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":165,"enrollmentInfo":329,"targetDuration":301,"studyType":117,"phases":4,"briefSummary":331,"conditions":332,"keywords":337,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":351,"leadSponsor":353,"locationsCount":47},"100625082","the-liver-cirrhosis-cognitive-decline-scale-liccos-100625082","NCT07418008","The Liver Cirrhosis Cognitive Decline Scale (LiCCoS)","Development and Psychometric Validation of The Liver Cirrhosis Cognitive Decline Scale (LiCCoS)","LiCCoS","Inclusion Criteria:\n\n* Age 18-75 years.\n* Documented clinical diagnosis of liver cirrhosis based on imaging, histology, or validated clinical criteria.\n* Able to read and understand the language of the cognitive tests.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>75 years\n* Known case of Overt Hepatic Encephalopathy defined as Grade II or higher on the West Haven criteria \\[25\\].\n* Use of central nervous system depressants, anticholinergics, or psychotropics initiated or changed within the past 4 weeks.\n* Known case of Severe uncorrected visual or hearing impairment limiting ability to complete cognitive testing.\n* Known case of Any neurological and psychological disorders, substance use disorder and sleep disorders.\n* Known case of Severe systemic illness (e.g., end-stage renal disease, decompensated heart failure) that may independently impair cognition or limit participation.",{"count":330,"type":22},230,"The goal of this observational study is to develop and test a new questionnaire called the Liver Cirrhosis Cognitive Decline Scale (LiCCoS) for adults with liver cirrhosis. This questionnaire is designed to help identify problems with thinking and daily mental functioning that are common in people with liver cirrhosis but are often missed during routine care.\n\nPeople with liver cirrhosis may experience problems such as forgetfulness, slowed thinking, trouble paying attention, or difficulty planning everyday tasks. These problems can affect daily life, safety, and treatment adherence. Existing cognitive tests often require special training or equipment and may not fully reflect how people experience these difficulties in daily life. This study aims to create a simple, patient-reported tool that captures these concerns in an easy and practical way.\n\nThe main questions this study aims to answer are:\n\n1. Can the LiCCoS questionnaire reliably measure cognitive difficulties in adults with liver cirrhosis?\n2. Does the questionnaire correctly reflect differences in cognitive function across levels of liver disease severity?\n3. Do LiCCoS scores relate to results from commonly used cognitive screening tests?\n\nParticipants will be adults aged 18 to 75 years who have a confirmed diagnosis of liver cirrhosis and are attending outpatient clinics. Participation is voluntary.\n\nParticipants will:\n\nProvide basic background information, such as age and medical history\n\nComplete the LiCCoS questionnaire about their thinking and daily mental functioning\n\nComplete standard cognitive screening tests commonly used in clinical care\n\nThis study does not involve any treatment or change in medical care. The information collected will be used only for research purposes. The results are expected to help develop a reliable and easy-to-use tool that can support early recognition of cognitive difficulties in people with liver cirrhosis and improve communication between participants and health care providers.",[333,334,335,336],"Liver Cirrhosis","Cognitive Dysfunction","Hepatic Encephalopathy","Neurocognitive Disorders",[327,338,339,340,341,342,343,344,345,346],"Liver cirrhosis","Cognitive impairment","Cognitive dysfunction","Hepatic encephalopathy","Patient-reported outcome measure","Psychometric validation","Scale development","Cognitive assessment","Chronic liver disease","2026-02-10",{"date":349,"type":39},"2026-02-18",{"date":317,"type":39},{"date":352,"type":22},"2026-11-30",{"name":45,"class":46},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":138,"enrollmentInfo":362,"targetDuration":4,"studyType":23,"phases":364,"briefSummary":365,"conditions":366,"keywords":370,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":4},"100623548","dexmedetomidine-for-postoperative-analgesia-and-delirium-prevention-after-neurosurgery-dex-neuro-trial-100623548","NCT07398066","DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery (DEX-NEURO Trial)","DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery: A Double-blinded Randomised Placebo-controlled Trial (DEX-NEURO Trial)","DEX-NEURO","Inclusion Criteria:\n\n* All adult (American Society of Anaesthesiologists (ASA 1-2) who \\>18 years old and \\\u003C65 years old undergoing elective craniotomy\n\nExclusion Criteria:\n\n* Patients who are ASA 3-5 or BMI \\\u003C18\u002F \\>40 or allergic to dexmedetomidine will be excluded. Patients with high-grade heart block or uncontrolled bradyarrhythmia will also be excluded.",{"count":363,"type":22},60,[25],"Post-craniotomy pain is common and often undertreated. Inadequate analgesia can lead to patient discomfort and higher opioid consumption, which may result in respiratory depression, sedation risks and impaired neurological assessment in the early postoperative period. The incidence of post-operative delirium after intracranial surgery was 19%, ranging from 12 to 26% caused by variation in clinical features and delirium assessment methods1. It is associated with increased morbidity, longer length of hospital stay, and harm to self or staffs.\n\nDexmedetomidine (Precedex) is a highly selective α2-adrenergic agonist with the properties of analgesia, sedative, anxiolytic and neuroprotection without significant respiratory depression. Most of the trials administered a loading dose of 0.5-1.0 μg\u002Fkg intravenous dexmedetomidine over 10 minutes followed by infusion dose 0.2-0.7 μg\u002Fkg\u002Fhour. The use of intraoperative dexmedetomidine is believed to reduce the usage of postoperative opioids where frequent neurological assessment is often required in neurosurgical patients. Beyond the benefit of analgesia, perioperative dexmedetomidine has been studied for prevention of postoperative delirium. Randomized trials in mixed noncardiac surgical populations reported that low-dose perioperative dexmedetomidine may reduce the incidence of delirium. Dexmedetomidine produces dose-dependent bradycardia and hypotension, which should be carefully monitored to maintain the cerebral perfusion pressure in brain surgery. However, most trials and meta-analyses have focused on general surgical or cardiac cohorts; the evidence remains limited in neurosurgical (craniotomy) patients.\n\nAlthough it showed promising benefits of analgesia and neuroprotection in non-neurosurgical patients, recent meta-analyses of intraoperative dexmedetomidine reported high degree of heterogeneity due to the inclusion of varied procedures (elective vs emergent craniotomy), dosing regimes (loading dose only versus loading dose + infusion versus infusion only) and varied primary endpoints (postoperative pain scores, cumulative opioid consumption or incidence of delirium). Therefore, this randomized, double-blind, placebo-controlled trial is designed to examine the use of intravenous dexmedetomidine in the reduction of postoperative pain score and delirium in neurosurgical patients. We hypothesised that intravenous dexmedetomidine reduces postoperative pain score and delirium with lower need of rescue analgesia and amount of morphine consumption in patients undergoing craniotomy.",[367,368,369],"Neurosurgery","Brain Cancer","Meningioma",[371,372,373,374,375],"dexmedetomidine","precedex","neurosurgery","delirium","pain",{"date":377,"type":39},"2026-02-09",{"date":379,"type":22},"2026-07-22",{"date":381,"type":22},"2027-08-22",{"name":45,"class":46},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":391,"minAge":19,"maxAge":138,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":393,"briefSummary":395,"conditions":396,"keywords":398,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":408,"locationsCount":4},"100604817","phase-4-study-comparing-dynastat-and-parestat-pain-relief-medications-for-patients-after-breast-surgery-100604817","NCT07154446","Study Comparing Dynastat and Parestat Pain Relief Medications for Patients After Breast Surgery","Dynastat vs. Parestat for Postoperative Analgesia in Breast Surgery: A Non-Inferiority Randomised Controlled Trial","PANDA","Inclusion Criteria:\n\nPatients aged 18 years or older. Patients scheduled for elective excision biopsy of the breast. Patients with an American Society of Anesthesiologists (ASA) physical status classification of I or II.\n\nPatients who can understand and provide written informed consent.\n\nExclusion Criteria:\n\nPatients with a known allergy or contraindication to parecoxib or any of its excipients.\n\nPatients with a history of severe gastrointestinal bleeding, ulceration, or perforation.\n\nPatients with a history of significant cardiovascular disease (e.g., unstable angina, recent myocardial infarction, stroke).\n\nPatients with uncontrolled hypertension. Patients with severe renal impairment (creatinine clearance \\\u003C 30 mL\u002Fmin). Patients with severe hepatic impairment (Child-Pugh Class C). Patients who are pregnant or breastfeeding. Patients taking medications that are contraindicated with parecoxib (refer to drug interaction section).\n\nPatients with a history of bronchospasm, acute rhinitis, nasal polyps, angioedema, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.","FEMALE",{"count":363,"type":22},[394],"PHASE4","The goal of this clinical trial is to learn if generic parecoxib (Parestat) works as well as the original drug (Dynastat) for treating pain after breast surgery. It will also learn about the safety of both drugs. The main questions it aims to answer are:\n\n* Does Parestat provide pain relief that is not inferior to the pain relief provided by Dynastat?\n* What medical problems (adverse events) do participants have when taking Parestat compared to Dynastat? Researchers will compare Parestat to Dynastat to see if the generic version also works to treat postoperative pain.\n\nParticipants will:\n\n* Be randomly assigned to receive either Dynastat or Parestat during their surgery.\n* Have their pain level assessed using the Visual Analog Scale (VAS) upon arrival in the recovery bay, 6 and 24 hours after surgery.\n* Be monitored for common side effects like nausea, vomiting, and changes in blood pressure for 24 hours.",[397],"Breast Exicision Biopsy",[399,400,401],"Randomised control trial","parecoxib","Breast excision biopsy","2025-09-16",{"date":404,"type":39},"2025-09-22",{"date":406,"type":22},"2025-10-01",{"date":105,"type":22},{"name":45,"class":46},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":416,"enrollmentInfo":417,"targetDuration":4,"studyType":23,"phases":418,"briefSummary":419,"conditions":420,"keywords":422,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":437,"locationsCount":47},"100606477","phase-4-dexmedetomidine-as-an-adjunct-to-periarticular-ropivacaine-in-total-knee-replacement-a-pilot-randomised-controlled-trial-100606477","NCT07176065","Dexmedetomidine as an Adjunct to Periarticular Ropivacaine in Total Knee Replacement: A Pilot Randomised Controlled Trial","A Pilot Randomized Controlled Trial Assessing the Impact of Dexmedetomidine as an Adjunct to Periarticular Ropivacaine Infiltration on Postoperative Pain and Recovery in Patients Undergoing Total Knee Replacement","Inclusion Criteria:\n\n* Aged ≥18 years\n* Undergoing elective unilateral total knee replacement\n* ASA physical status I-III\n* No known allergy to local anaesthetics or dexmedetomidine\n* No opioid use \\>24 hours preoperatively\n* Provided informed consent\n\nExclusion Criteria:\n\n* Known allergy to study drugs\n* Chronic pain or neurological conditions\n* Bilateral or revision TKR\n* Significant deformity affecting function\n* Substance abuse history\n* Day-case surgery","100 Years",{"count":363,"type":22},[394],"This study aims to evaluate whether adding dexmedetomidine to ropivacaine-based periarticular infiltration (PAI) improves postoperative pain control in patients undergoing total knee replacement (TKR). Despite standard pain management, many patients continue to experience moderate-to-severe pain after surgery. Dexmedetomidine, a sedative and analgesic agent, may help prolong the effect of local anaesthetics. A total of 60 patients will be randomly assigned to receive either ropivacaine alone or ropivacaine with dexmedetomidine. Pain scores, opioid use, side effects, and recovery time will be monitored for 24 hours. The goal is to determine if this method is more effective and safer for improving recovery after knee surgery.",[421],"Postoperative Pain Management in Total Knee Arthroplasty",[423,424,425,426,427,428,429,430,431],"Total Knee Replacement","TKR","Periarticular Infiltration","Ropivacaine","Dexmedetomidine","Postoperative Pain","Opioid Consumption","Regional Anaesthesia","Adductor Canal Block","2025-09-08",{"date":402,"type":39},{"date":435,"type":22},"2025-10",{"date":231,"type":22},{"name":45,"class":46},{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":23,"phases":447,"briefSummary":448,"conditions":449,"keywords":451,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":468,"locationsCount":47},"100598276","pharmacist-led-digital-interventions-to-improve-tuberculosis-treatment-adherence-100598276","NCT07069387","Pharmacist-led Digital Interventions to Improve Tuberculosis Treatment Adherence","Comprehensive Digital Adherence and Remote Engagement to Optimise Treatment Adherence for Tuberculosis Patients (CARE-TB Study) in Selangor, Malaysia: An Effectiveness-Implementation Science Study","CARE-TB","Inclusion Criteria:\n\n1. Microbiologically confirmed pulmonary TB (smear- or culture-positive PTB)\n2. 18 years old or older\n3. Able to give consent and physically able to participate in the study\n4. Own a video-recording device with internet connectivity\n5. Within the first 3 weeks of intensive phase TB treatment\n\nExclusion Criteria:\n\n1. Complicated TB disease including TB meningitis, TB bone\u002Fjoint, and disseminated TB with planned treatment duration of 9 to 12 months.\n2. Confirmed or suspected drug-resistant (DR)-TB\n3. Documented cognitive, motor, or visual disability that will hinder video device use and lack assistance of a caretaker\n4. Receiving injectable anti-TB drugs\n5. Incarceration or other involuntary detention",{"count":88,"type":22},[25],"The gold standard for tuberculosis (TB) treatment support requires directly observed therapy (DOT), which means a trained health worker observes the patient swallow each dose of medication every day for 2 months. Despite the practice of DOT in Malaysia, 1 in 20 patients are loss-to-follow-up and non-adherent to treatment. Sub-optimal adherence due to poor treatment acceptability and social desirability promotes TB treatment failure, disease relapse, on-going transmission, drug resistance, and death. Telemedicine offers a flexible and less invasive option to support TB treatment adherence. Despite 97% internet and smartphone penetration rates, the practical implementation of digital adherence strategies to support and monitor TB treatment remains untested in Malaysia. The investigators propose to design, implement, and measure the effectiveness of a comprehensive, pharmacist-led digital solution for TB treatment support called CARE-TB which combines a package of asynchronous video-observed therapy, digital reminders, telecounselling and e-learning. In this multi-method effectiveness-implementation (Type 2) study using the Exploration, Preparation, Implementation and Sustainment (EPIS) framework, the investigators aim 1) To identify patient and provider-level facilitators and barriers to CARE-TB adoption via qualitative evaluation and to design a stakeholder-informed implementation strategy, (2) To assess effectiveness of CARE-TB strategy by evaluating (i) implementation outcomes, (ii) patient health outcomes, and (iii) service outcomes, and (3) To evaluate the cost-effectiveness of CARE-TB compared to standard of care from a societal perspective. This study will leverage digital platforms to expand the reach of TB adherence support, enhance adherence to TB treatment and improve treatment completion rates, while utilising existing personnel and resources in among the busiest TB treatment centres in the country.",[450],"Tuberculosis (TB)",[452,453,454,455,456,457,458,459,460,461],"tuberculosis","active tuberculosis","monitoring","video observed therapy","education","pharmacist","digital","implementation science","cost","motivational","2025-07-07",{"date":464,"type":39},"2025-07-16",{"date":466,"type":39},"2025-04-07",{"date":103,"type":22},{"name":45,"class":46},{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":18,"minAge":267,"maxAge":476,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":479,"briefSummary":480,"conditions":481,"keywords":485,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":47},"100588704","microbial-adherence-surface-roughness-effectiveness-and-impact-on-patients-between-conventional-and-3d-printed-twin-block-appliances-100588704","NCT06944860","Microbial Adherence, Surface Roughness, Effectiveness and Impact on Patients Between Conventional and 3D Printed Twin Block Appliances","Microbial Adherence, Surface Roughness, Effectiveness and Impact on Patients Between Conventional and 3D Printed Twin Block Appliances: An Open-Label Prospective Clinical Trial","Inclusion Criteria:\n\n1. Patients with Class II Division 1 incisor relationship\n2. Overjet of ≥ 7mm\n3. Age range of children: 10-12 years in females, 12-14 years in males\n4. All permanent incisors and molars erupted\n5. ICDAS ≥ score 3 and BPE ≥ 3\n6. Able to understand English or Bahasa Melayu\n\nExclusion Criteria:\n\n1. Patients with craniofacial syndromes (example: cleft lip and palate)\n2. Patients with previous history of orthodontic treatment\n3. Patients with hyperdivergent facial type (MMPA \\> 40º)\n4. Untreated gingival disease (e.g.: gingivitis, periodontitis)","14 Years",{"count":478,"type":22},32,[25],"The Twin Block appliance is a removable orthodontic appliance that is used to help correct a backward positioned lower jaw in growing children. This appliance works by guiding the lower jaw forward to a specific position over a certain period of time. After completing the treatment, patients often experience improvements in their appearance, such as an improved bite, a more balanced facial profile and improved lip posture.\n\nThe investigators' interest is to compare two types of Twin Block appliances; traditional (conventional) and 3D-printed, by examining several factors, including the amount of bacteria that stick to them, the surface roughness, and the overall effectiveness of each type.\n\nSurface roughness refers to the texture of the appliance's surface, which could influence how much bacteria can accumulate. Rougher surfaces may trap more bacteria, potentially leading to oral health issues such as bad breath, tooth decay, and gum problems. The study will also assess the effectiveness of both the conventional and 3D-printed Twin Block appliances, focusing on factors like how well they perform in improving jaw position and achieving the desired treatment outcomes.\n\nAdditionally, the investigators want to assess how these appliances affect the quality of life related to oral health. Participants will answer questions about their experience to help understand how the type of appliance impacts their daily lives, comfort, and overall well-being during the course of treatment.",[482,483,484],"Orthodontic Appliances, Removable","Orthodontic Appliance Complication","Class II Malocclusion, Division 1",[486,487,488,489,490],"Twin block appliance","Microbial adherence","Surface roughness","Effectiveness","Oral Health Related Quality of Life (OHRQoL)","2025-06-15",{"date":493,"type":39},"2025-06-18",{"date":495,"type":39},"2025-05-01",{"date":497,"type":22},"2027-01-17",{"name":45,"class":46},{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":506,"enrollmentInfo":507,"targetDuration":4,"studyType":23,"phases":509,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":519,"locationsCount":47},"100583049","dietary-modification-in-inflammatory-bowel-disease-patients-100583049","NCT06871267","Dietary Modification In Inflammatory Bowel Disease Patients","Dietary Modification In Patients With Inflammatory Bowel Diseases And Its Impact In Gut Microbiome","Inclusion Criteria:\n\n* Confirmed diagnosis of Crohn's disease according to established clinical, endoscopic, and histological criteria.\n* Mild to moderate diseases (150 to 220 points).\n* Written informed consent obtained.\n\nExclusion Criteria:\n\n* Presence of stoma.\n* Surgery within 6 months prior to randomization.\n* Patient on exclusive enteral nutrition (EEN).","50 Years",{"count":508,"type":22},74,[25],"This research project aimed to develop a culturally appropriate Asian Inflammatory Bowel Disease Diet for the Malaysian population, based on the Crohn's disease exclusion diet (CDED). The study will be conducted in inflammatory bowel disease patients in University Malaya Medical Centre, which are ulcerative colitis and Crohn's disease patients. The objectives of this study are to assess the impact of diet in clinical outcome and gut microbiota changes in patients with inflammatory bowel disease (IBD). The study duration spans 24 weeks, during which comprehensive follow-ups will be conducted at 0, 6, 12, and 24 weeks, respectively. At each follow-up session, participants will be requested to provide stool and blood samples for meticulous assessment of clinical and biochemical responses.",[512],"Crohn Disease","2025-05-27",{"date":515,"type":39},"2025-05-31",{"date":517,"type":39},"2025-03-01",{"date":347,"type":22},{"name":45,"class":46},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":18,"minAge":267,"maxAge":528,"enrollmentInfo":529,"targetDuration":4,"studyType":23,"phases":530,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":542},"100568367","preoperative-carbohydrate-drink-in-adolescent-idiopathic-scoliosis-surgery-the-impact-on-safety-and-enhanced-recovery-100568367","NCT06680297","Preoperative Carbohydrate Drink in Adolescent Idiopathic Scoliosis Surgery: the Impact on Safety and Enhanced Recovery","A Pilot Study on Preoperative Carbohydrate Loading in Adolescent Idiopathic Scoliosis Surgery: the Impact on Safety and Enhanced Recovery","CARBO-AIS","Inclusion Criteria:\n\n* Patient diagnosed with idiopathic scoliosis undergoing single-staged posterior spinal fusion\n* Age between 10 to 19 years old\n* ASA 1 \\& 2\n\nExclusion Criteria:\n\n* Patient diagnosed with diabetes mellitus (either type I or type II)\n* Patient with intellectual disability\n* American Society of Anesthesiologists (ASA) class 3 and above\n* Significant risk of aspiration (diagnosed with hiatal hernia, presence of GERD, BMI \\> 35 kg\u002Fm2 , poor GCS, swallowing abnormality, gastrointestinal abnormality)","19 Years",{"count":363,"type":22},[25],"The goal of this interventional study is to learn if carbohydrates loading improves overall outcome in adolescent patient undergoing scoliosis curgery\n\nThe main questions of the study are as follows:\n\n1. Does carbohydrates loading improves gastrointestinal related problems such as improvement in return of bowel function measured by first passage of flatus, reduce constipation by patient's time to first bowel opening and reduce incidence of post post operative nausea and vommiting\n2. Does carbohydrates loading reduces length of hospital stay and patient's overall condition in term of anxiety, thirst and hunger\n3. Does carbohydrates loading affects gastric residual volume by measuring residual gastric volume with ultrasound",[533],"Adolescent Idiopathic Scoliosis","2025-05-06",{"date":536,"type":39},"2025-05-11",{"date":538,"type":39},"2024-11-12",{"date":540,"type":22},"2025-12-31",{"name":45,"class":46},2,{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":549,"eligibilityCriteria":550,"healthyVolunteers":17,"sex":18,"minAge":267,"maxAge":4,"enrollmentInfo":551,"targetDuration":4,"studyType":23,"phases":552,"briefSummary":553,"conditions":554,"keywords":557,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":542},"100557651","phase-4-a-comparison-between-palonosetron-versus-granisetron-as-ponv-prophylaxis-in-scoliotic-patients-undergoing-spine-surgery-100557651","NCT06540885","A Comparison Between Palonosetron Versus Granisetron as PONV Prophylaxis in Scoliotic Patients Undergoing Spine Surgery","A Comparison Between Palonosetron Versus Granisetron As Postoperative Nausea and Vomiting Prophylaxis In Idiopathic Scoliosis Surgery: A Randomized Control Trial","PONV","Inclusion Criteria:\n\n* Age: 10 years and above\n* American Society of Anesthesiologists (ASA) class I-II\n\nExclusion Criteria:\n\n* Active smoker\n* Obesity with body mass index (BMI) of 34 and above\n* Body weight of less than 30kg\n* History of gastro-esophageal reflux disease (GERD)\u002F other gastrointestinal diseases associated with vomiting\n* History of motion sickness\n* History of allergy to 5-HT3 (serotonin) receptor antagonists or dexamethasone\n* History of nausea or vomiting withing 24 hours before surgery\n* History of administration of antiemetics\u002F steroids\u002F psychoactive medications within 24 hours before the surgery\n* History of cardiac arrhythmias\n* Prolonged QT (QTc is prolonged if \\> 430ms in men or \\>450ms in women)",{"count":508,"type":22},[394],"The aim of this clinical trial is to compare the effectiveness of two Serotonin (5- HT3) receptor antagonist, palonosetron and granisetron, administered along with dexamethasone as a preventive measure against early and delayed postoperative nausea and vomiting (PONV) in adult and adolescent patients with idiopathic scoliosis (IS) undergoing posterior spinal fusion (PSF) surgery under total intravenous anesthesia (TIVA).\n\nThe main questions the study aims to answer are:\n\nHow effective is palonosetron compared to granisetron, when both combined with dexamethasone, in preventing PONV after scoliosis surgery? Are there any differences in the need for rescue antiemetics, occurrence of adverse effects related to the study drugs, and patient satisfaction between the two treatment groups? Participants in the study will be randomly assigned to receive either palonosetron or granisetron in addition to dexamethasone as part of their anesthesia and antiemetic regimen. The incidence and\u002F or severity of nausea, vomiting and retching will be assessed at 1 hour, 4 hours, 12 hours, 24 hours and 48 hours after surgery.",[555,556],"Postoperative Nausea and Vomiting","Scoliosis",[558,559,560],"Antiemetics","Granisetron","Palonosetron","2025-04-22",{"date":563,"type":39},"2025-04-25",{"date":565,"type":39},"2025-01-06",{"date":567,"type":22},"2026-09-30",{"name":45,"class":46},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":576,"enrollmentInfo":577,"targetDuration":4,"studyType":23,"phases":578,"briefSummary":580,"conditions":581,"keywords":4,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":47},"100588880","early-phase-1-pilot-study-of-throat-packs-soaked-in-gengigel-spray-in-patients-undergoing-elective-surgery-100588880","NCT06947161","Pilot Study of Throat Packs Soaked in Gengigel Spray in Patients Undergoing Elective Surgery","The Pilot Study of Throat Packs Soaked in Gengigel Spray in Patients Undergoing Elective Surgery Under General Anaesthesia","Inclusion Criteria:\n\n1. Classified as ASA I-II, indicating a relatively low risk of complications from anesthesia\n2. Aged between 18 and 60 years, which represents a typical adult surgical population\n3. Both male and female patients, ensuring gender inclusivity and representation in the study findings\n\nExclusion Criteria:\n\n1. Existing sore throat prior to surgery, which could affect the baseline measurement of postoperative sore throat.\n2. Anticipation of a difficult airway, as these patients may require specialized intubation techniques that are not standardized across the study.\n3. More than two attempts at endotracheal tube (ETT) insertion, as multiple attempts could cause additional trauma and skew the study outcomes.\n4. Any trauma occurring during intubation, which could independently contribute to postoperative sore throat and other complications","60 Years",{"count":363,"type":22},[579],"EARLY_PHASE1","Throat packs are commonly used in many surgical procedures involving the oral cavity and pharynx, primarily to prevent blood, saliva, and other debris from entering the lower respiratory tract, thereby maintaining a clear airway and reducing the risk of aspiration and respiratory complications. Traditionally, these packs are moistened with saline or used in a dry state, with the choice often depending on the surgeon's preference and specific surgical requirements. However, despite their widespread usage, the exploration of alternative substances to moisten throat packs, particularly those with additional therapeutic benefits, remains limited in medical research. This pilot study introduces Gengigel spray as an innovative alternative to saline for moistening throat packs. Gengigel, a hyaluronic acid (HA)-based product, is known for its healing properties and anti-inflammatory effects, which are beneficial in oral care. Gengigel provides a non-anesthetic approach that promotes tissue repair and reduces inflammation. This makes it particularly advantageous in the context of surgical procedures where reducing postoperative inflammation and promoting mucosal healing are crucial.",[582],"Throat, Sore","2025-04-19",{"date":585,"type":39},"2025-04-27",{"date":587,"type":39},"2025-02-12",{"date":589,"type":22},"2025-08-12",{"name":45,"class":46},{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":4,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":598,"targetDuration":4,"studyType":23,"phases":600,"briefSummary":601,"conditions":602,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":611,"locationsCount":47},"100576000","implementation-and-effectiveness-of-careaide-app-for-people-with-cardiometabolic-diseases-at-a-primary-care-clinic-100576000","NCT06779591","Implementation and Effectiveness of \"CareAide® App\" for People with Cardiometabolic Diseases At a Primary Care Clinic","Implementation and Effectiveness of the Medication Adherence \"CareAide® App\" for People with Cardiometabolic Diseases At an Academic Primary Care Clinic in Malaysia: a Hybrid Implementation-effectiveness Study","Inclusion Criteria:\n\n* Above 18 years old\n* Medically diagnosed with either hypertension, type 2 diabetes and dyslipidemia for at least 6 months as listed in electronic health records\n* Exhibit a low adherence indicated by Malaysia Medication Adherence Assessment Tool (MyMAAT) scores of \\\u003C54 scores\n* Taking at least one type of medication daily, three medications daily or two medications with multiple dosing intervals prescribed,\n* Owns and able to use a smartphone\n* Able to read English or Malay\n\nExclusion Criteria:\n\n* Individuals who are pregnant, already using any adherence apps or diagnosed with any terminal illnesses, visually impaired, disability or mental health related illnesses",{"count":599,"type":22},200,[25],"This study aims to explore the barriers and facilitators to implement CareAide® app among healthcare providers and patients at a primary care clinic in Malaysia.\n\nThis is an implementation-qualitative research study meaning researchers will collect data regarding the adoption rate, ease of implementation and adoption, and patient's willingness to use the application. The researchers will also compare the effectiveness of the application as a tool to remind patients to take their medicine, by comparing between a group of participants who use the app and another group of participants who do not use the app.\n\nThis study requires participants to use an app, then attend some routine follow-ups and be administered blood tests, followed by an interview to collect their opinions, feelings, and experiences.",[603,305,604],"Hypertension","Dyslipidemia","2025-03-25",{"date":607,"type":39},"2025-03-30",{"date":609,"type":22},"2025-04-30",{"date":105,"type":22},{"name":45,"class":46},{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":391,"minAge":19,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":23,"phases":621,"briefSummary":622,"conditions":623,"keywords":626,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":631,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":636,"locationsCount":47},"100584506","impact-of-perioperative-nutrition-intervention-on-bioimpedance-phase-angle-ipenipa-in-breast-cancer-patients-100584506","NCT06890221","Impact of PErioperative Nutrition Intervention on Bioimpedance Phase Angle (IPENIPA) In Breast Cancer Patients","Impact of PErioperative Nutrition Intervention on Bioimpedance Phase Angle (IPENIPA) In Breast Cancer Patients: A Double-Blinded Randomized Controlled Trial","IPENIPA","Inclusion Criteria:\n\n* Female\n* Histopathologically confirmed operable breast cancer\n* Aged 18 of years and above\n* Consented and scheduled for mastectomy\n\nExclusion Criteria:\n\n* On enteral supplementation prior to the study\n* Lactose intolerance\n* Pregnant or lactating\n* Previous history of gastrectomy or small bowel resection surgery\n* Advanced breast cancer staging, presence of pacemaker, decompensated liver disease, end stage renal failure, uncontrolled diabetes, on steroid therapy or complementary traditional medications",{"count":269,"type":22},[25],"The goal of this clinical trial is to measure the mean difference of phase angle after nutritional intervention in breast cancer patients. The main question it aims to answer is:\n\n1\\. Can perioperative nutrition interventions improve phase angle in relation to other bioimpedance parameters, handgrip strength and surgical outcomes in breast cancer population?\n\nResearchers will compare oral nutritional supplement to a placebo to see if oral nutritional supplement can improve phase angle.\n\nParticipants will:\n\n1. Be randomized into either arm\n2. Take oral nutritional supplement or placebo according to the result of randomization for 7 days preoperatively and 30 days postoperatively\n3. Have their measurements (weight, height, phase angle, handgrip strength) done at least 7 days preoperative, 1 day preoperative and 30 days postoperative",[624,625],"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","Mastectomy Patient",[627,628,629],"bioimpedance phase angle","nutritional intervention","oral nutritional supplement","2025-03-21",{"date":632,"type":39},"2025-03-26",{"date":634,"type":39},"2025-03-07",{"date":155,"type":22},{"name":45,"class":46},{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":4,"eligibilityCriteria":643,"healthyVolunteers":17,"sex":18,"minAge":644,"maxAge":645,"enrollmentInfo":646,"targetDuration":4,"studyType":23,"phases":648,"briefSummary":649,"conditions":650,"keywords":653,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":658,"lastUpdatePostDateStruct":659,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":665,"locationsCount":47},"100545422","effectiveness-of-mysmile-app-for-improving-the-oral-health-of-secondary-school-children-100545422","NCT06381700","Effectiveness of MySmile App for Improving the Oral Health of Secondary School Children:","Effectiveness of MySmile App for Improving the Oral Health of Secondary School Children: A Cluster Randomised Controlled Trial","1. Inclusion criteria for school\n\n   * Government-funded secondary school\n   * Received SDS from the mobile dental squad\u002Fschool dental clinic at least once a year.\n   * High-risk schools with all indicators not meeting the district's benchmark.\n2. Inclusion criteria for the participants:\n\n   * Secondary school children aged 15-17 years old.\n   * Medium to high dental plaque level - Plaque score more than 50%\n   * Healthy with no chronic medical history and physical disabilities\n   * Understand the English language.\n   * Own a smartphone\u002F\u002F have access to an Android-based smartphone","15 Years","17 Years",{"count":647,"type":22},303,[25],"The goal of this cluster-randomised control trial is to assess the effectiveness of the MySmile app for improving oral health in secondary school children. The main questions it aims to answer are:\n\n1. Will the MySmile app be more effective in improving secondary school children's dental plaque and gingival health over and above the existing school dental service (SDS)?\n2. Will the MySmile app be more effective in improving secondary school children's oral health knowledge, attitudes, and behaviours over and above the existing SDS?\n3. Is the MySmile app easy to use by secondary school children?\n4. Is the MySmile app acceptable to use from the perspective of secondary school children?\n\nParticipants in the intervention group will receive the SDS and MySmile app. The control group will receive SDS only. Therefore the researcher will compare between the intervention and control group in terms of dental plaque, gingival health, oral health knowledge, oral health attitudes and oral health behaviours.",[651,652],"Oral Disease","Gingival Diseases",[654,655,656,657],"Mobile apps","Prevention","Oral Health Promotion","Schoolchildren","2025-03-11",{"date":660,"type":39},"2025-03-12",{"date":662,"type":22},"2025-03",{"date":664,"type":22},"2025-08",{"name":45,"class":46},{"id":667,"slug":668,"hasResults":12,"nctId":669,"briefTitle":670,"officialTitle":671,"acronym":4,"eligibilityCriteria":672,"healthyVolunteers":17,"sex":18,"minAge":673,"maxAge":267,"enrollmentInfo":674,"targetDuration":4,"studyType":23,"phases":676,"briefSummary":677,"conditions":678,"keywords":681,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":684,"lastUpdatePostDateStruct":685,"startDateStruct":686,"completionDateStruct":688,"leadSponsor":690,"locationsCount":47},"100574485","comparison-between-protraction-facemask-and-upper-braces-for-underbite-correction-in-growing-children-100574485","NCT06759896","Comparison Between Protraction Facemask and Upper Braces for Underbite Correction in Growing Children","Comparison Between Protraction Facemask and Upper Partial Fixed Appliance for Early Class III Intervention: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age group between 7 to 10 years\n2. Three or four incisors in crossbite\n3. Positive overbite\n4. Class III skeletal with ANB equal to or less than 0 or retrusive maxilla\n5. Amount of crowding equal to or less than 4 mm\n6. Good oral hygiene\n\nExclusion Criteria:\n\n1. Cleft lip and palate and\u002For craniofacial syndrome\n2. Patients with syndromes or medical condition\n3. Subjects involved in any other orthodontic trials\n4. A maxilla-mandibular planes angle greater than 35 degree\n5. Previous history of TMJ signs or symptoms\n6. Lack of consent","7 Years",{"count":675,"type":22},24,[25],"The goal of this clinical trial is to compare the effectiveness of a protraction facemask and upper partial fixed appliance in correcting anterior crossbite in growing children with class III malocclusion. It will also learn about the patients perceptions of these treatments. The main questions it aims to answer are:\n\ni. What is the rate of success in achieving anterior crossbite correction with the protraction facemask and upper partial fixed appliance? ii. Are there any significant differences in the dental, skeletal and soft tissue outcomes between the two treatment groups? iii. What are the patient's perceptions associated with each treatment modality received.\n\niv. What is the incidence of adverse effects or complications and breakages associated with each treatment modality?\n\nParticipants will be randomly assigned to one of two groups: 1) protraction facemask; or 2) upper partial fixed appliance. After investigators decide which group participants will be in, investigators will take some standard records for the study before starting the treatment. These records include:\n\n1. Making moulds of their teeth to create study models\n2. Taking a side-view X-ray of their head (called a lateral cephalometric radiograph)\n\nAdditionally, the participant will need to fill out a quick 5-minute survey called the Child Perceptions Questionnaire 8-10 (CPQ8-10). It has 25 short questions. The participant will do this survey at four different times: 1) before starting the treatment; 2) 3 months into the treatment; 3) 6 months into the treatment; and 4) after the treatment is done.\n\nInvestigators will set up appointments for the treatment based on the type assigned. Once the treatment starts, investigators will see the participant every six weeks until it is finished.\n\nIf the participant gets a protraction facemask, investigators will put a fixed expander appliance in the mouth at the palate. Investigators will teach them how to activate the appliance once a day for seven days. Afterwards, the participant will use the protraction facemask with elastics connecting the appliance in the mouth and the protraction facemask. The participant must wear it for 14 hours a day, at night.\n\nIf the participants gets an upper fixed partial appliance, investigators will bond upper fixed appliances in the mouth.\n\nInvestigators will teach the child how to clean the appliance and their mouth to avoid any potential problems or side effects during the treatment.",[679,680],"Anterior Crossbite","Class III Malocclusion in Growing Patients",[682,683],"Randomized controlled trial","anterior crossbite","2024-12-29",{"date":565,"type":39},{"date":687,"type":39},"2024-07-26",{"date":689,"type":22},"2025-12-30",{"name":45,"class":46},""]